Anne V Gonzalez1, Janie Coulombe2, Pierre Ernst2, Samy Suissa3. 1. Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, McGill University Health Centre, Montreal, QC. 2. Centre for Clinical Epidemiology, Jewish General Hospital - Lady Davis Research Institute, Montreal, QC, Canada. 3. Centre for Clinical Epidemiology, Jewish General Hospital - Lady Davis Research Institute, Montreal, QC, Canada. Electronic address: samy.suissa@mcgill.ca.
Abstract
BACKGROUND: It is uncertain whether long-term use of inhaled corticosteroids (ICSs), widely used to treat COPD, increases the risk of fracture, particularly in women, in view of the postmenopausal risks. We assessed whether long-term ICS use in patients with COPD increases the risk of hip or upper extremity fractures, and examined sex-related differences. METHODS: The Quebec health-care databases were used to form a cohort of patients with COPD over 1990 to 2005, followed until 2007 for the first hip or upper extremity fracture. In a nested case-control analysis, each case of fracture was matched with 20 control subjects on age, sex, and follow-up time. The adjusted rate ratio (RR) of fracture with ICS use, by duration and dose, was estimated using conditional logistic regression, with an interaction term to compare the risk in men and women. RESULTS: In the cohort of 240,110 subjects, 19,396 sustained a fracture during a mean 5.3 years (rate, 15.2 per 1,000 per year). Any use of ICSs was not associated with an increased rate of fracture (RR, 1.00; 95% CI, 0.97-1.03). The fracture rate was increased with > 4 years of ICS use at daily doses ≥ 1,000 μg in fluticasone equivalents (RR, 1.10; 95% CI, 1.02-1.19). This risk increase did not differ between men and women. CONCLUSIONS: Long-term ICS use at high doses is associated with a modest increase in the risk of hip and upper extremity fractures in patients with COPD. This dose-duration risk increase does not appear to be higher for women.
BACKGROUND: It is uncertain whether long-term use of inhaled corticosteroids (ICSs), widely used to treat COPD, increases the risk of fracture, particularly in women, in view of the postmenopausal risks. We assessed whether long-term ICS use in patients with COPD increases the risk of hip or upper extremity fractures, and examined sex-related differences. METHODS: The Quebec health-care databases were used to form a cohort of patients with COPD over 1990 to 2005, followed until 2007 for the first hip or upper extremity fracture. In a nested case-control analysis, each case of fracture was matched with 20 control subjects on age, sex, and follow-up time. The adjusted rate ratio (RR) of fracture with ICS use, by duration and dose, was estimated using conditional logistic regression, with an interaction term to compare the risk in men and women. RESULTS: In the cohort of 240,110 subjects, 19,396 sustained a fracture during a mean 5.3 years (rate, 15.2 per 1,000 per year). Any use of ICSs was not associated with an increased rate of fracture (RR, 1.00; 95% CI, 0.97-1.03). The fracture rate was increased with > 4 years of ICS use at daily doses ≥ 1,000 μg in fluticasone equivalents (RR, 1.10; 95% CI, 1.02-1.19). This risk increase did not differ between men and women. CONCLUSIONS: Long-term ICS use at high doses is associated with a modest increase in the risk of hip and upper extremity fractures in patients with COPD. This dose-duration risk increase does not appear to be higher for women.
Authors: Rosa M R Pereira; Mariana O Perez; Ana Patrícia Paula; Caio Moreira; Charlles H M Castro; Cristiano A F Zerbini; Diogo S Domiciano; Elaine de Azevedo; Laura M C Mendonca; Marcia Midore Shinzato; Marco Antonio A da Rocha-Loures; Sebastião Radominski; Vera L Szejnfeld Journal: Arch Osteoporos Date: 2021-03-01 Impact factor: 2.617
Authors: Ralph Kwame Akyea; Tricia M McKeever; Jack Gibson; Jane E Scullion; Charlotte E Bolton Journal: BMJ Open Date: 2019-04-03 Impact factor: 2.692
Authors: Jadwiga A Wedzicha; Dave Singh; Ioanna Tsiligianni; Christine Jenkins; Sebastian Fucile; Robert Fogel; Steven Shen; Pankaj Goyal; Karen Mezzi; Konstantinos Kostikas Journal: Respir Res Date: 2019-01-08
Authors: Alexander Egeberg; Peter Schwarz; Torben Harsløf; Yuki M F Andersen; Anton Pottegård; Jesper Hallas; Jacob P Thyssen Journal: JAMA Dermatol Date: 2021-03-01 Impact factor: 10.282
Authors: David B Price; Jaco Voorham; Guy Brusselle; Andreas Clemens; Konstantinos Kostikas; Jeffrey W Stephens; Hye Yun Park; Nicolas Roche; Robert Fogel Journal: NPJ Prim Care Respir Med Date: 2019-10-28 Impact factor: 2.871